Below is an educational, technical answer to a question many patients and clinicians ask. When a narrowing becomes flow-limiting, patients may experience angina on exertion, and an abrupt plaque rupture with thrombosis can precipitate a myocardial infarction. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
Contemporary practice relies heavily on drug-eluting stents, which release an antiproliferative agent to limit the tissue overgrowth that can cause restenosis. During PCI a lesion is usually crossed with a guidewire, prepared with a balloon, and in most cases scaffolded with a stent that holds the vessel open. Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery.
What is recovery like after a heart stent?
Because PCI is minimally invasive and often uses radial access, many patients mobilize within hours and return to light activity within a few days. Access-site care, prescribed medications, and cardiac risk-factor management are typical parts of aftercare. Recovery can be longer when a stent is placed in the setting of an acute myocardial infarction. Specific activity timelines are set by the treating clinician based on the individual case.
What This Means in Practice
Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes. Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes.
Key Considerations
- Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy.
- Lesion calcification is a central factor in planning, and heavily calcified plaque may call for rotational atherectomy before ballooning or stenting.
- Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes.
Frequently Asked Questions
What is the reported restenosis performance of the ATLAS DES?
INVAMED reports clinical data showing target lesion revascularization rates below 5% at 12 months; this reflects studied performance and is not an individual guarantee.
What drug does the ATLAS stent release?
According to INVAMED, the ATLAS DES elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile.
Are these coronary devices CE marked?
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
When a narrowing becomes flow-limiting, patients may experience angina on exertion, and an abrupt plaque rupture with thrombosis can precipitate a myocardial infarction. Because a drug-coated balloon leaves nothing behind, it is one option a clinician may weigh when a metallic implant is less desirable. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes. Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery. INVAMED's ATLAS system elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile designed to cover the early healing window. All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU. Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk. Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- What should be avoided after stent placement?
- Atlas Coronary Stent System Cobalt Chromium — Technical Overview
- Drug-eluting stent or Bare-metal stent? A Technical Comparison
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.